Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.80 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.80 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing ongoing efforts in clinical development. They did not provide specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs despite the current financial results.
Madrigal Pharmaceuticals reported a loss per share of $1.80, which did not meet any consensus expectations. The stock reacted negatively, declining by 1.23%. Investors may be concerned about the lack of revenue information and forward guidance, which could indicate uncertainty about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2020